Phathom Pharmaceuticals, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$12.57
−$1.00 (−7.34%) 4:00 PM ET
After hours$13.00
+$0.44 (+3.46%) 5:11 PM ET
Prev closePrevC$13.56
OpenOpen$13.54
Day highHigh$13.68
Day lowLow$12.32
VolumeVol1,165,696
Avg volAvgVol1,019,902
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$979.85M
P/E ratio
-3.33
FY Revenue
$147.19M
EPS
-3.77
Gross Margin
87.25%
Sector
Healthcare
AI report sections
MIXED
PHAT
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals shows very strong recent price performance with the stock closing at the top of its 52-week range and materially above key moving averages. At the same time, fundamentals remain deeply loss-making with negative equity and heavy cash burn despite solid revenue growth. Elevated short interest and overbought technical readings indicate heightened positioning and volatility risk around the current level.
U.S. stock futures declined on Thursday with investors awaiting Supreme Court ruling on tariffs and December jobs reports. AZZ surged on strong earnings, Northrop Grumman jumped on defense spending proposals, while Immuneering tumbled on disappointing trial data and Phathom dropped following stock offering announcement. Constellation Brands rose on better-than-expected earnings.
Stock dropped 14.22% following announcement of $130 million public offering of common stock and pre-funded warrants, causing dilution concerns.
PositiveGlobeNewswire Inc.• Na
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
Phathom Pharmaceuticals priced a $130 million underwritten public offering consisting of 6.875 million shares of common stock at $16.00 per share and 1.25 million pre-funded warrants at $15.999 per warrant. The offering is expected to close on January 9, 2026, with net proceeds intended for general corporate purposes including working capital, commercialization, and R&D expenses. Guggenheim Securities and Cantor are serving as joint bookrunning managers.
The company successfully priced a substantial $130 million capital raise, demonstrating investor confidence and providing significant funding for commercialization and R&D activities. This capital infusion supports the company's growth strategy for its marketed GI disease treatments.
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
Phathom Pharmaceuticals will participate in the American College of Gastroenterology's 2025 Annual Scientific Meeting, showcasing VOQUEZNA® (vonoprazan) as an approved treatment for Gastroesophageal Reflux Disease (GERD) through product theater presentations and exhibit booth interactions.
Company is actively promoting its GERD treatment, highlighting leadership in gastrointestinal medicine, and engaging with medical community at a prominent scientific conference
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Phathom Pharmaceuticals will host a live webcast on October 30, 2025, at 8:00 am EDT to report its third quarter 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.
Standard financial reporting announcement with no explicit positive or negative indicators, routine business communication about quarterly results
NeutralGlobeNewswire Inc.• Nick Benedetto
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
Phathom Pharmaceuticals announced administrative changes to a Schedule 13D filing by Frazier Life Sciences, emphasizing that these changes do not represent a reduction in ownership position, but rather reflect reporting approach modifications.
PHATSchedule 13Downershipreportingpharmaceutical
Sentiment note
Company proactively clarifying potential misunderstandings about shareholder ownership, demonstrating transparency
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Phathom Pharmaceuticals will host a live webcast on August 7, 2025, at 8:00 am EDT to report its Q2 2025 financial results and provide a business update, focusing on their gastrointestinal disease treatments.
Standard financial reporting announcement with no explicit positive or negative indicators, routine business communication about quarterly results
PositiveGlobeNewswire Inc.• N/A
Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors
Phathom Pharmaceuticals, a biopharmaceutical company, announced the appointment of Ted Schroeder, a seasoned biopharma leader, to its Board of Directors. Schroeder's deep operational and commercial expertise is expected to be an important asset as Phathom continues to unlock the full potential of its lead product, VOQUEZNA.
PHATPhathom PharmaceuticalsTed SchroederBoard of DirectorsVOQUEZNA
Sentiment note
The article highlights Phathom's appointment of a seasoned biopharma leader to its Board of Directors, which is expected to be an important asset as the company continues to commercialize its lead product, VOQUEZNA. This suggests a positive outlook for the company's future growth and development.
Phathom Pharmaceuticals has appointed Steven Basta as its new President and CEO, succeeding Terrie Curran. Basta is an experienced biopharmaceutical leader who will focus on accelerating the commercial growth of Phathom's lead product, VOQUEZNA.
The article highlights Phathom's strong foundation and the board's confidence in Basta's ability to further accelerate the company's commercial growth and deliver critical treatments for patients, which suggests a positive outlook for the company.
PositiveGlobeNewswire Inc.• N/A
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported strong commercial performance for its GERD treatment VOQUEZNA, with $55.3 million in 2024 net revenues and over 300,000 filled prescriptions. The company also announced plans to initiate a Phase 2 trial for VOQUEZNA in eosinophilic esophagitis.
The article highlights Phathom's strong commercial performance for its GERD treatment VOQUEZNA, with significant revenue and prescription growth, as well as plans to expand its pipeline into eosinophilic esophagitis.
PositiveGlobeNewswire Inc.• N/A
Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
Phathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal diseases, announced that members of its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities SMID Cap Biotech Conference.
PHATPhathom Pharmaceuticalsgastrointestinal diseasesGuggenheim Securities SMID Cap Biotech Conference
Sentiment note
The article highlights Phathom Pharmaceuticals' participation in an industry conference, which suggests the company is actively engaged in its business and seeking to raise its profile.
PositiveGlobeNewswire Inc.• N/A
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
Phathom Pharmaceuticals, a biopharmaceutical company, will host a live webcast on November 7, 2024, to report its third quarter 2024 financial results and provide a business update.
The article announces that Phathom Pharmaceuticals will be reporting its financial results and providing a business update, which suggests the company is actively engaged in its operations and making progress.
PositiveInvesting.com• The Tokenist
The Top 3 Most-Shorted Stocks in August
The article discusses the top 3 most-shorted stocks in August, including Beyond Meat (BYND), Phathom Pharmaceuticals (PHAT), and Groupon (GRPN). It analyzes the short interest, financial performance, and market outlook for each company.
Phathom Pharmaceuticals has a high short interest of 48.64% of its float, with 14.6 days to cover. The company's flagship product, vonoprazan, received FDA approval in July for the treatment of non-erosive GERD. Despite a net loss and accumulated deficit, the stock is up nearly 40% year-to-date and has a forecasted average price target of $22 per share.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
